Blood and Marrow Transplant State of the Science Symposium

血液和骨髓移植科学现状研讨会

• 批准号: 7277455
• 负责人: JAMES L. M. FERRARA
• 金额: $ 2万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7277455
• 关键词: Agreement; Allogenic; American Society of Hematology; Blood; Cell Transplantation; Chairperson; Clinical; Clinical Research; Clinical Trials Network; Collection; Communities; Conduct Clinical Trials; Disease; Goals; Heart; Hematology; Hematopoietic; Institutes; Leadership; Lung; Malignant - descriptor; Marrow; Medical; Methods; Michigan; Morbidity - disease rate; National Cancer Institute; Non-Malignant; Numbers; Oral; Outcome; Patient Selection; Patients; Publishing; Purpose; Recommendation; Research; Risk; Science; Stem cells; Supportive care; Techniques; Time; Transplantation; United States; improved; mortality; novel; symposium

DESCRIPTION (provided by applicant): This proposal seeks support for the organization of a "State of the Science" Symposium in Hematopoietic Cell Transplantation (HCT) to be held in Ann Arbor, Michigan on June 26-27, 2007. Thousands of HCTs are performed to treat malignant and non-malignant diseases each year. Current estimates of annual numbers of HCTs are about 45,000 worldwide, with 15-20,000 annually in the United States. Reasons for increasing use include proven and potential efficacy in many diseases, better understanding of appropriate timing and patient selection, greater availability of donors and better techniques for determining HLA match, greater ease of stem cell collection, and improved supportive care. Despite these improvements, application of HCT is still limited by relatively high risks of morbidity and mortality and, in the case of allogeneic HCT, availability of suitable donors. In 2001, The National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI) jointly established a Blood and Marrow Transplant Clinical Trials Network (BMT CTN). The network's overarching goal is to conduct clinical trials that will definitively answer key questions in current HCT medical practice that can improve patient outcomes by assessing novel HCT methods and management strategies in a multi-center setting. The purpose of this symposium is to identify the most compelling clinical research opportunities that can be initiated in the next five years by the BMT CTN, and to disseminate its conclusions among the BMT and Hematology scientific communities. The recommendations of the first symposium, held in 2000, guided the scientific agenda of the BMT CTN during its first five years, and we expect the second symposium's recommendations to be equally important. The BMT CTN leadership has already formed twelve committees to evaluate recent advances in translational and clinical HCT research, and has received agreement from twelve distinguished leaders in the field to act as committee chairpersons. Importantly, we intend to publish the recommendations of the symposium and we plan oral presentations of the symposium's major findings at the 2007 ASH meeting and the 2008 Tandem meeting.

描述（由申请人提供）： 该提案寻求支持组织将于 2007 年 6 月 26 日至 27 日在密歇根州安娜堡举行的造血细胞移植（HCT）“科学状况”研讨会。进行了数千次 HCT 来治疗恶性和非造血细胞移植。每年都有恶性疾病。目前估计全世界每年的 HCT 数量约为 45,000 例，其中美国每年为 15-20,000 例。增加使用的原因包括在许多疾病中已证实和潜在的疗效、更好地了解适当的时机和患者选择、更容易获得捐赠者和更好的确定 HLA 匹配的技术、更容易采集干细胞以及改善支持性护理。尽管有这些改进，HCT 的应用仍然受到相对较高的发病率和死亡率风险的限制，并且在同种异体 HCT 的情况下，缺乏合适的供体。 2001年，国家心肺血液研究所（NHLBI）和国家癌症研究所（NCI）联合建立了血液和骨髓移植临床试验网络（BMT CTN）。该网络的总体目标是开展临床试验，明确回答当前 HCT 医疗实践中的关键问题，通过在多中心环境中评估新颖的 HCT 方法和管理策略来改善患者的治疗结果。 本次研讨会的目的是确定 BMT CTN 在未来五年内可以发起的最引人注目的临床研究机会，并在 BMT 和血液学科学界传播其结论。这 2000 年举行的第一次研讨会的建议指导了 BMT CTN 头五年的科学议程，我们预计第二次研讨会的建议同样重要。 BMT CTN 领导层已成立了 12 个委员会来评估转化和临床 HCT 研究的最新进展，并已获得该领域 12 名杰出领导人的同意担任委员会主席。 重要的是，我们打算公布研讨会的建议，并计划在 2007 年 ASH 会议和 2008 年 Tandem 会议上口头介绍研讨会的主要发现。